Abstract
Aims. To investigate the efficacy of letrozole 2.5mg and 10mg used as primary neoadjuvant therapy for patients with locally advanced and large operable breast cancer.
Patients and Methods. Twenty-four postmenopausal patients with locally advanced or large operable breast cancer were treated in two consecutive series with letrozole 2.5mg (n=12) or letrozole 10mg (n=12). Response at three months was measured by change in tumor volume according to WHO criteria (partial response was defined as a reduction in tumor volume ≥65%). Tumor volumes were assessed clinically, by ultrasound and mammography, and pathologically.
Results. All 24 patients were estrogen receptor-positive, were considered ‘receptor-rich’, and mean age was 77.6 years and 71.6 years in the letrozole 2.5mg and 10mg treatment groups, respectively. There were five complete clinical responses and seven partial clinical responses in the patients treated with 2.5mg letrozole, and nine partial responses and three patients with stable disease in patients treated with 10mg letrozole. Assessed by ultrasound and mammography, the 12 patients treated with 2.5mg had one complete response, nine partial responses and two with no change. In the 12 patients treated with 10mg letrozole, imaging gave eight partial responses and four with no change. One patient treated with the 2.5mg dose had a complete clinical and pathological response. There was no significant difference between the two doses in effect on tumor volume, and no recordable side effects associated with either dose.
Conclusion. Letrozole used in a neoadjuvant setting is highly effective, producing clinically beneficial reductions in tumor volume allowing all patients to have breast conserving surgery, and has an acceptable safety profile.
References
Corry JFG, Lønning PE: Systematic therapy in breast cancer: efficacy and cost utility. Pharmacoeconomics 5: 198-212, 1994
Jordan VC: Tamoxifen for breast cancer prevention. Proc Soc Exp Biol Med 208: 144-149, 1995
Early Breast Cancer Trialists' Research Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339: 1-15, 1992
Anderson EDC, Forrest APM, Levack PA, Chetty U, Hawkins RA: Response to endocrine manipulation and oestrogen receptor concentration in large, operable breast cancer. Br J Cancer 60: 223-226, 1989
Hamilton A, Piccart M: The third generation nonsteroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann Oncol 10: 377-384, 1999
Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomised trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16: 453-461, 1998
Gershanovich M, Chaudri HA, Campos D, Lurie H, Bonaventura A, Jeffrey M, Buzzi F, Bodrogi I, Ludwig H, Reichardt P, O'Higgins N, Romieu G, Friederich P, Lassus M: Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5mg daily with 0.5mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol 9: 639-645, 1998
McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr: Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109: 716-721, 1985
Forouhi P, Walsh JS, Anderson TJ, Chetty U: Ultrasonography as a method of measuring breast tumour size and monitoring response to primary systemic therapy. Br J Surg 81: 223-225, 1994
James VHT, McNeill JM, Lai LC, Newton CJ, Ghilchik MW, Reed MJ: Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies. Steroids 50: 269-279, 1987
Reed MJ, Owen AM, Lai C, Coloham NG, Ghilchik MW, Shaikh NA, James VHT: In situ oestrone synthesis in normal breast and breast tumour tissues. Int J Cancer 44: 233-237, 1989
Hayward JL, Carbone PP, Heusen JC, Kumaoka S, Segaloff A, Rubens RD: Assessment of response to therapy in advanced breast cancer. Br J Cancer 35: 292-298, 1977
WHO Handbook for Reporting Results of Cancer Treatment (Response Criteria), World Health Organization, Geneva, Publication Number 48, 1979
Keen JC, Dixon JM, Miller EP, Cameron DA, Chetty U, Hanby A, Bellamy C, Miller WR: Expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer. Br Cancer Res Treat 44: 123-133, 1994
Grunberg SM: Consistent definitions of tumour response. J Clin Oncol 4: 609-610, 1986
Miller WR, Telford J, Smith H, Dixon JM: Effect of neoadjuvant treatment with the aromatase inhibitor letrozole onperipheral synthesis of oestrogen, uptake by the breast and in situ production of oestrogen within mammary tissues. Br Cancer Res Treat 50: 228, 1998
Hunt KE, Fry DE, Bland KI: Breast carcinoma in the elderly patient: an assessment of operative risk, morbidity and mortality. Am J Surg 140: 339-342, 1980
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dixon, J., Love, C., Bellamy, C. et al. Letrozole as Primary Medical Therapy for Locally Advanced and Large Operable Breast Cancer. Breast Cancer Res Treat 66, 191–199 (2001). https://doi.org/10.1023/A:1010669403283
Issue Date:
DOI: https://doi.org/10.1023/A:1010669403283